Mast cell chymase affects the proliferation and metastasis of lung carcinoma cells in vitro

Jiang,Yuan; Wu,Yudan; Hardie,William  James; Zhou,Xiaoying

doi:10.3892/ol.2017.6487

Mast cell chymase affects the proliferation and metastasis of lung carcinoma cells in vitro

Authors:
- Yuan Jiang
- Yudan Wu
- William James Hardie
- Xiaoying Zhou
View Affiliations

Affiliations: School of Pharmaceutical Engineering and Life Sciences, Changzhou University, Changzhou, Jiangsu 213164, P.R. China
Published online on: June 28, 2017 https://doi.org/10.3892/ol.2017.6487
Pages: 3193-3198

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis of lung carcinoma cells is a major cause of organ failure and mortality of patients with lung cancer. Lung mast cells are a type of immune cell which reside in the respiratory mucosa. High numbers of mast cells are associated with the majority of common types of cancer; however, the effects of mast cells on cancer remain unclear. In the present study, the effects of mast cell chymase (MCC) on the proliferation and adhesion of the lung carcinoma cell lines A549 and H520 was investigated. After 24 h of treatment, the highest dose of MCC (50 mU/ml) decreased the proliferation rate of A549 and H520 cells, whereas the lowest dose of MCC (5 mU/ml) resulted in a small increase in the viability. A549 cells treated with MCC lost adhesion ability in a MCC dose‑dependent manner; however, these detached cells were able to regrow when transferred to a fresh culture. The protein expression of epithelial (E‑) cadherin, p53 and p21 in A549 lung carcinoma cells were detected by western blot analysis. The results of the present study revealed that, following 24 h of treatment, the expression level of E‑cadherin was decreased, the p53 tumor suppressor protein was expressed in limited quantities and the expression of p21 was decreased. Zymography was used to examine the effects of MCC on the expression and activation of matrix metalloproteinase‑9 (MMP‑9) in A549 and H520 cells. The expression of MMP‑9 in the two cell lines was time‑ and MCC dose‑dependent. The results of the present study demonstrated that MCC stimulated lung carcinoma cell proliferation and adhesion, as well as regulated E‑cadherin expression and the cell cycle, all of which are associated with cancer metastasis. Therefore, MCC may be a potential candidate for lung carcinoma therapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
3	Krishnaswamy G, Ajitawi O and Chi DS: The human mast cell: An overview. Methods Mol Biol. 315:13–34. 2005.
4	Takanami I, Takeuchi K and Naruke M: Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer. 88:2686–2692. 2000. View Article : Google Scholar : PubMed/NCBI
5	Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB and Huntsman DG: Stromal mast cells in invasive breast cancer are a marker of favorable prognosis: A study of 4,444 cases. Breast Cancer Res Treat. 107:249–257. 2008. View Article : Google Scholar : PubMed/NCBI
6	Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, Stattin P, Egevad L, Granfors T, Wikström P and Bergh A: Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol. 177:1031–1041. 2010. View Article : Google Scholar : PubMed/NCBI
7	Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, Strouch M, Weitz J, Koch M, Halverson AL, Bentrem DJ and Khazaie K: In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci USA. 107:pp. 6430–6435. 2010; View Article : Google Scholar : PubMed/NCBI
8	Ozdemir O: The role of mast cell density in tumor-associated angiogenesis and survival of squamous cell carcinoma of the lung. J Cancer Res Ther. 11:10412015. View Article : Google Scholar : PubMed/NCBI
9	Khazaie K, Blatner NR, Khan MW, Gounari F, Gounaris E, Dennis K, Bonertz A, Tsai FN, Strouch MJ, Cheon E, et al: The significant role of mast cells in cancer. Cancer Metastasis Rev. 30:45–60. 2011. View Article : Google Scholar : PubMed/NCBI
10	Nagata M, Shijubo N, Walls AF, Ichimiya S, Abe S and Sato N: Chymase-positive mast cells in small sized adenocarcinoma of the lung. Archiv Für Pathologische Anatomie Und Physiologie Und Für Klinische Medicin. 443:565–573. 2003.
11	Maltby S, Khazaie K and McNagny KM: Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta. 1796:19–26. 2009.PubMed/NCBI
12	Theoharides TC, Angelidou A and Zhang B: Mast cells and tumor microenvironment. Cancer Drug Discovery Development. 1–370. 2010.
13	Stewart JA Jr, Wei CC, Brower GL, Rynders PE, Hankes GH, Dillon AR, Lucchesi PA, Janicki JS and Dell'Italia LJ: Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J Mol Cell Cardiol. 35:311–319. 2003. View Article : Google Scholar : PubMed/NCBI
14	Seth D, D'Souza El-Guindy NB, Apte M, Mari M, Dooley S, Neuman M, Haber PS, Kundu GC, Darwanto A, de Villiers WJ, et al: Alcohol, signaling, and ECM turnover. Alcohol Clin Exp Res. 34:4–18. 2010. View Article : Google Scholar : PubMed/NCBI
15	Christensen J and Shastri VP: Matrix-metalloproteinase-9 is cleaved and activated by Cathepsin K. Bmc Res Notes. 8:3222015. View Article : Google Scholar : PubMed/NCBI
16	Murnane MJ, Cai J, Shuja S, McAneny D, Klepeis V and Willett JB: Active MMP-2 effectively identifies the presence of colorectal cancer. Int J Cancer. 125:2893–2902. 2009. View Article : Google Scholar : PubMed/NCBI
17	Cupić DF, Tesar EC, Ilijas KM, Nemrava J and Kovacević M: Expression of matrix metalloproteinase 9 in primary and recurrent breast carcinomas. Coll Antropol. 35 Suppl 2:S7–S10. 2011.
18	Werner G, Daniele M, Gabriella N, Lorenzo M, Giovanni T and Renato G: Association between metalloproteinases 2 and 9 activity and ERK1/2 phosphorylation status in head and neck cancers: An ex vivo study. Oncol Rep. 24:1073–1078. 2010.PubMed/NCBI
19	Lecuit T and Yap AS: E-cadherin junctions as active mechanical integrators in tissue dynamics. Nat Cell Biol. 17:533–539. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhao P, Guo S, Tu Z, Di L, Zha X, Zhou H and Zhang X: Grhl3 induces human epithelial tumor cell migration and invasion via downregulation of E-cadherin. Acta Biochim Biophys Sin (Shanghai). 48:266–274. 2016. View Article : Google Scholar : PubMed/NCBI
21	Techasen A, Loilome W, Namwat N, Khuntikeo N, Puapairoj A, Jearanaikoon P, Saya H and Yongvanit P: Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis. Tumour Biol. 35:8645–8652. 2014. View Article : Google Scholar : PubMed/NCBI
22	Chen A, Beetham H, Black MA, Priya R, Telford BJ, Guest J, Wiggins GA, Godwin TD, Yap AS and Guilford PJ: E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. Bmc Cancer. 14:5522014. View Article : Google Scholar : PubMed/NCBI
23	Muller PA and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
24	Sivoňová MK, Vilčková M, Kliment J, Mahmood S, Jurečeková J, Dušenková S, Waczulíková I, Slezák P and Dobrota D: Association of p53 and p21 polymorphisms with prostate cancer. Biomed Rep. 3:707–714. 2015.PubMed/NCBI
25	Ribatti D and Crivellato E: Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta. 1822:2–8. 2012. View Article : Google Scholar : PubMed/NCBI
26	Zhou X, Cox C, Rajenthirar S, Mahrous AA, Masters B, Roche WR and Walls AF: Mast cell Chymase Can Disrupt the human bronchial epithelium and stimulate the loss of adhesion molecules. J Allergy Clinical Immunol. 121:S1102008. View Article : Google Scholar
27	Lee HS and Daar IO: EphrinB reverse signaling in cell-cell adhesion: Is it just par for the course? Cell Adh Migr. 3:250–255. 2008. View Article : Google Scholar
28	Segal L, Katz LS, Shapira H, Sandbank J, Geras-Raaka E, Gershengorn MC and Oron Y: PAR-3 knockdown enhances adhesion rate of PANC-1 cells via increased expression of integrinαv and E-cadherin. PLoS One. 9:e938792014. View Article : Google Scholar : PubMed/NCBI
29	Cui T, Srivastava AK, Han C, Yang L, Zhao R, Zou N, Qu M, Duan W, Zhang X and Wang QE: XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression. Oncotarget. 6:10060–10072. 2015. View Article : Google Scholar : PubMed/NCBI
30	Waldum HL, Ringnes E, Nordbø H, Sørdal Ø, Nordrum IS and Hauso Ø: The normal neuroendocrine cells of the upper gastrointestinal tract lack E-cadherin. Scand J Gastroentero. 49:974–978. 2014. View Article : Google Scholar
31	Yamashita N, Tokunaga E, Inoue Y, Tanaka K, Ueo H, Saeki H, Oki K and Maehara Y: Abstract P2-05-12: Epithelial paradox; clinical significance of co-expression of E-cadherin and vimentin in invasive breast cancer. Cancer Res. 76:2016. View Article : Google Scholar
32	Wu CL, Ho JY, Chou SC and Yu DS: MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer. Oncotarget. 7:26593–26603. 2016. View Article : Google Scholar : PubMed/NCBI
33	Dass SD, Cheah PL, Ong DB, Teoh KH and Looi LM: E-cadherin downregulation at the infiltrating tumour front is associated with histological grade and stage in colorectal carcinoma of Malaysians. Malays J Pathol. 37:19–24. 2015.PubMed/NCBI
34	Nam RK, Benatar T, Wallis CJ, Amemiya Y, Yang W, Garbens A, Naeim M, Sherman C, Sugar L and Seth A: MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence. Prostate. 76:869–884. 2016. View Article : Google Scholar : PubMed/NCBI
35	Ma B, Zhang HY, Bai X, Wang F, Ren XH, Zhang L and Zhang MZ: ADAM10 mediates the cell invasion and metastasis of human esophageal squamous cell carcinoma via regulation of E-cadherin activity. Oncol Rep. 35:2785–2794. 2016.PubMed/NCBI
36	Wang X, Simpson ER and Brown KA: p53: Protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Res. 75:5001–5007. 2015. View Article : Google Scholar : PubMed/NCBI
37	McNaughton M, Pitman M, Pitson SM, Pyne NJ and Pyne S: Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramidedesaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget. 7:16663–16673. 2016. View Article : Google Scholar : PubMed/NCBI
38	Liu Z, Liu Z, Zhang X, Xue P and Zhang H: RY10-4 suppressed metastasis of MDA-MB-231 by stabilizing ECM and E-cadherin. Biomed Pharmacother. 68:439–445. 2014. View Article : Google Scholar : PubMed/NCBI
39	Sullu Y, Demirag GG, Yildirim A, Karagoz F and Kandemir B: Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract. 207:747–753. 2011. View Article : Google Scholar : PubMed/NCBI
40	Peng WJ, Zhang JQ, Wang BX, Pan HF, Lu MM and Wang J: Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clinica Chim Acta. 413:1121–1126. 2012. View Article : Google Scholar